ArticlePloS one2015
Role of Procalcitonin and Interleukin-6 in Predicting Cancer, and Its Progression Independent of Infection.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Procalcitonin-Guided Management and Duration of Antibiotic Therapy in Critically Ill Cancer Patients With Sepsis (Pro-Can Study): A Randomized Controlled Trial.Critical care explorations · 2024Trial
- Marked Non-Infectious Elevation of Procalcitonin in a Hemodialysis Patient with Bladder Cancer: A Case Report.Infection and drug resistance · 2026Article
- Diagnostic Accuracy of Procalcitonin in the Diagnosis of Sepsis in Cancer Patients Hospitalized for Infection.Cancer reports (Hoboken, N.J.) · 2025Observational
- Highly elevated sepsis biomarkers in advanced cholangiocarcinoma without sepsis: A case report and literature review.Medicine · 2025Review
- High procalcitonin level is related to blood stream infections, gram-negative pathogens, and ICU admission in infections of adult febrile cancer patients.Journal of the Egyptian National Cancer Institute · 2025Article
- Article
- Review
- Hemophagocytic Lymphohistiocytosis Associated With T-cell Lymphoma in Pregnancy: Diagnostic Conundrum Unveiled.Cureus · 2024Article
- Serum procalcitonin as a tumor marker in lung adenocarcinoma with ovarian metastasis: a case report.Annals of medicine and surgery (2012) · 2023Article
- The Utility of Pre-Treatment Inflammation Markers as Associative Factors to the Adverse Outcomes of Vulvar Cancer: A Study on Staging, Nodal Involvement, and Metastasis Models.Journal of clinical medicine · 2022Article
- Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Procalcitonin and C-reactive protein in the diagnosis of spontaneous bacterial peritonitis.Translational gastroenterology and hepatology · 2022Article
- The role of procalcitonin in identifying high-risk cancer patients with febrile neutropenia: A useful alternative to the multinational association for supportive care in cancer score.Cancer medicine · 2021Article
- Biomarkers and Fever in Children with Cancer: Kinetics and Levels According to Final Diagnosis.Children (Basel, Switzerland) · 2021Article
- Article
- Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection.Gynecologic oncology · 2020Article
- Utility of procalcitonin as a predictor of bloodstream infections and supportive modality requirements in critically ill cancer patients.Clinica chimica acta; international journal of clinical chemistry · 2020Article
- Serum Procalcitonin in Patients With Combined Lung Cancer and Idiopathic Pulmonary Fibrosis (LC-IPF).Cureus · 2020Article
- Diagnostic Accuracy of Procalcitonin, Neutrophil-to-Lymphocyte Ratio, and C-Reactive Protein in Detection of Bacterial Infections and Prediction of Outcome in Nonneutropenic Febrile Patients with Lung Malignancy.Journal of oncology · 2020Article
- Procalcitonin Level in Non-Small Cell Lung Cancer Patients among Indonesian Population.Open access Macedonian journal of medical sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Procalcitonin (PCT) and Interleukin-6 (IL-6) have emerged as biomarkers for different inflammatory conditions. The purpose of the study was to evaluate the role of PCT and IL-6 as biomarkers of cancer and its progression in a large cohort of patients. This cross-sectional study included residual plasma samples collected from cancer patients, and control subjects without cancer. Levels of PCT and IL-6 were determined by Kryptor compact bioanalyzer. We identified 575 febrile cancer patients, 410 non-febrile cancer patients, and 79 non-cancer individuals. The median PCT level was lower in control subjects (0.029 ng/ml) compared to cancer patients with stage I-III disease (0.127 ng/ml) (p<0.0001) and stage IV disease (0.190 ng/ml) (p<0.0001). It was also higher in febrile cancer patients (0.310 ng/ml) compared to non-febrile cancer patients (0.1 ng/ml) (p<0.0001). Median IL-6 level was significantly lower in the control group (0 pg/ml) than in non-febrile cancer patients with stages I-III (7.376 pg/ml) or stage IV (9.635 pg/ml) (p<0.0001). Our results suggest a potential role for PCT and IL-6 in predicting cancer in non-febrile patients. In addition, PCT is useful in detecting progression of cancer and predicting bacteremia or sepsis in febrile cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.